$TNYA

Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported Q4 EPS of (12c), matching the consensus estimate. CEO Faraz Ali highlighted clinical progress in 2025 and anticipates further updates in the first half of 2026 for its gene therapy programs TN-201 and TN-401. The company also presented positive preclinical data for its HDAC6 inhibitor, TN-301, showing improvements in Duchenne muscular dystrophy models.

Original reporting
Insider Monkey · Jeff Lewis
Published Mar 20, 2026, 12:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 20, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus — source image
Decision brief

The 30-second read

$TNYANeutralMed
01

Why it matters

The positive clinical data and earnings alignment suggest a stable outlook, but the biotech sector's volatility warrants caution.

02

Market read

The company's clinical progress and earnings report are relevant for biotech investors, with potential sector-wide implications.

03

What to watch

Regulatory hurdles or clinical trial failures could negatively impact stock; broader market conditions may influence biotech sector performance.

Timing: short-term (next 1-3 months)

Background

Tenaya Therapeutics is advancing gene therapy programs and HDAC6 inhibitors, with recent clinical updates and earnings reports.

Company-level read

Ticker impact

$TNYANeutralMedium confidence
Context

The news reports quarterly earnings and clinical progress, indicating ongoing development and potential future catalysts.

Expected impact

Limited immediate price movement; potential for upward movement if clinical progress translates into valuation uplift.

Evidence & confidence

Earnings in line with consensus suggest no immediate surprise; clinical progress is positive but may not be fully priced in yet.

Market effects

Potential positive impact on biotech and gene therapy sectors

Limited regional impact, primarily affecting US biotech stocks

Moderate, as biotech developments can influence global health markets

Counterpoint

Clinical progress may be already priced in; any delays or setbacks could lead to downside risk.

Key entities

  • Tenaya Therapeutics, Inc.

    A biotech firm focused on gene therapy and neurodegenerative disease treatments.

  • TN-201

    A gene therapy program in clinical development.

  • TN-401

    Another gene therapy candidate in early stages.

  • TN-301

    An HDAC6 inhibitor showing promise in preclinical models.

Related articles

$TNYAMed

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya Therapeutics (NASDAQ:TNYA) said it plans Q4 updates for gene therapy TN-401 in PKP2-associated ARVC, with early data showing ~60% to 67% PVC reductions across patients (up to 52 weeks). It also reported Phase 1 results for TN-301 (72 patients) and Phase 2-enabling work. Tenaya had ~$78M cash and a $10M upfront Alnylam deal.

$TNYAMed

Tenaya Therapeutics, Inc. (TNYA): Results of Operations and Financial Condition

Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tnya-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements

$TNYAMedAI 9/10

Tenaya's TN-201 Gene Therapy Shows Sustained Cardiac Improvements In MYBPC3-Associated HCM

Tenaya Therapeutics reported interim MyPEAK-1 Phase 1b/2 data for TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic cardiomyopathy. As of a May 2026 cutoff, six evaluable patients showed improvements in echocardiographic hypertrophy and symptom measures; three improved exercise capacity. Company said benefits were sustained up to two years in Cohort 1 and earlier in Cohort 2. PRIME and FDA rare disease processes apply.

$XOMMed

ExxonMobil $1.1bn pre-FID contracts for Rovuma LNG phase one

ExxonMobil Mozambique said it awarded about $1.1bn in pre-investment contracts for phase one of the Rovuma LNG project in Mozambique’s Area 4, covering long-lead subsea equipment, valves and offshore export line pipe. The awards were issued for Area 4 partners ENH, CNPC, Eni, KOGAS and XRG, supporting progress toward a final investment decision. The onshore plant is designed for ~18.6 mtpa LNG.

$LHXMed

Sam Mehta Named L3Harris President, CEO

L3Harris Technologies appointed Sam Mehta as president and CEO, effective immediately, and added him to the board. Christopher Kubasik stepped down as chairman and CEO after the company said it learned of conduct inconsistent with its code of conduct. Lewis Hay III became independent chairman. Lauren Barnes and Christopher Aebli took over Mehta’s prior segments; L3Harris reiterated a $3 billion capital buildout.

Med

Einride to deploy 500 Tesla electric trucks for North American fleet

Einride AB said it will deploy 500 Tesla electric trucks across its North American operations over the next two years, starting September 2026 and completing in phases through 2028. The company said the rollout would support customers including Amazon and triple its electric truck fleet. Einride also cited 19 million electric miles logged by its AI monitoring system and aims to convert about $800 million in potential annual recurring revenue into active capacity.